Collectively, these data strongly suggest that CD38 upregulation, irrespective of the specific used approach, results in the improved anti-MM activity of NAD+-depleting agents, with oxidative stress that appears to be crucial in managing the impact of this strategy among MM patients. This evidence concerns the gene CD38 and Miyoshi myopathy.